Mount Sinai School of Medicine, Mount Sinai School of Medicine, New York, NY.
Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA.
Chest. 2011 Mar;139(3):491-496. doi: 10.1378/chest.09-2547. Epub 2010 Jun 24.
Although lobectomy is the standard treatment for stage I non-small cell lung cancer (NSCLC), recent studies have suggested that limited resection may be a viable alternative for small-sized tumors. The objective of this study was to compare survival after lobectomy and limited resection among patients with stage IA tumors≤1 cm by using a large, US-based cancer registry.
Using the Surveillance, Epidemiology, and End Results (SEER) registry, we identified 2,090 patients with stage I NSCLC≤1 cm in size who underwent lobectomy or limited resection (segmentectomy or wedge resection). We used propensity score analysis to adjust for potential differences in the baseline characteristics of patients in the two treatment groups. Overall and lung cancer-specific survival rates of patients undergoing lobectomy vs limited resection were compared in stratified and adjusted analyses, controlling for propensity scores.
Overall, 688 (33%) patients underwent limited resection. For the entire cohort, we were not able to identify a difference in outcomes among patients treated with lobectomy vs limited resection, as demonstrated by an adjusted hazard ratio (HR) for overall survival (1.12; 95% CI, 0.93-1.35) and lung cancer-specific survival (HR, 1.24; 95% CI, 0.95-1.61). Similarly, when the cohort was divided into propensity score quintiles, we did not find a difference in survival rate between the two groups.
Limited resection and lobectomy may lead to equivalent survival rates among patients with stage I NSCLC tumors≤1 cm in size. If confirmed in prospective studies, limited resection may be preferable for the treatment of small tumors because it may be associated with fewer complications and better postoperative lung function.
尽管肺叶切除术是治疗 I 期非小细胞肺癌(NSCLC)的标准治疗方法,但最近的研究表明,对于小尺寸肿瘤,有限切除术可能是一种可行的替代方法。本研究的目的是使用基于美国的大型癌症登记处,比较≤1cm ⅠA 期肿瘤患者行肺叶切除术和有限切除术(肺段切除术或楔形切除术)后的生存情况。
我们使用监测、流行病学和最终结果(SEER)登记处,确定了 2090 名接受了肺叶切除术或有限切除术(肺段切除术或楔形切除术)的大小≤1cm 的Ⅰ期 NSCLC 患者。我们使用倾向评分分析来调整两组患者基线特征的潜在差异。在分层和调整分析中,比较肺叶切除术与有限切除术患者的总生存率和肺癌特异性生存率,同时控制倾向评分。
总体而言,有 688 名(33%)患者接受了有限切除术。对于整个队列,我们无法确定接受肺叶切除术与有限切除术的患者在结局上存在差异,总生存率的调整危险比(HR)为 1.12(95%CI,0.93-1.35)和肺癌特异性生存率(HR,1.24;95%CI,0.95-1.61)。同样,当将队列分为倾向评分五分位数时,我们也没有发现两组之间的生存率存在差异。
对于大小≤1cm 的Ⅰ期 NSCLC 肿瘤患者,有限切除术和肺叶切除术可能导致相似的生存率。如果在前瞻性研究中得到证实,有限切除术可能更适合治疗小肿瘤,因为它可能与更少的并发症和更好的术后肺功能相关。